Women's Health Condition Gets Name That Finally Fits

A confusing name for a common women's health condition just got fixed after one of the most thorough renaming processes in medical history.

Polycystic ovary syndrome, known as PCOS, is now officially polyendocrine metabolic ovarian syndrome, or PMOS. The new name was revealed Tuesday in The Lancet after more than a decade of work involving 22,000 doctors, researchers, patients, and advocates from around the globe.

The old name caused real problems. Despite affecting up to 13% of women of reproductive age, an estimated 70% of people with the condition go undiagnosed. Part of the reason? The name focused on ovarian cysts, which aren't actually the main feature of the condition.

"Doctors would focus on the cystic presentation, and patients could be dismissed if they didn't present with cysts, even as they suffered from the metabolic and fertility issues," said Rachel Morman, chair of trustees at Verity, a UK charity for PCOS patients.

Women with the condition experience weight gain, acne, irregular and painful periods, fertility challenges, and mental health issues. But because the old name was misleading, many doctors missed the diagnosis entirely.

The renaming journey started dramatically in 2015 at a meeting in Sicily where experts couldn't agree on anything except that the name was bad. Over the next ten years, the process became remarkably democratic. Three rounds of surveys asked thousands of stakeholders what they wanted most from a new name.

The top priorities? Avoiding stigma, making it easier to communicate about, and ensuring scientific accuracy. People wanted the name to reflect that the condition involves the endocrine system and affects metabolism, not just ovaries.

Why This Inspires

In a world where women's health often gets overlooked, this story shows what's possible when the medical community actually listens. The team at Monash University in Australia led workshops with participants from every corner of the globe and every interest group. They gave patients an equal voice alongside doctors and researchers.

When the final vote came earlier this year, 87 out of 90 voters immediately supported PMOS. By the time the paper was submitted, only two people still had reservations, mostly because they wanted to account for a potential male version of the condition that some early research suggests might exist.

But patient advocates like Morman argued that waiting to include men would have delayed help for millions of women who need better diagnosis and treatment now. "I fundamentally do not agree that waiting for a name change and then potentially changing it to encapsulate men is a wise thing to do," she said.

The new name keeps "ovarian" because it encompasses the hormonal changes and follicle responses in the ovary, according to lead researcher Helena Teede. Other options like using "reproductive" were considered too stigmatizing in many cultures.

Now comes the work of spreading the word about PMOS so that more women can get the diagnosis and care they deserve.